Proprietary Antisense Technology Platform: Ionis possesses a leading and highly refined antisense oligonucleotide (ASO) drug discovery platform, enabling the precise targeting of RNA to modulate protein expression and address a wide range of diseases.

Deep and Diverse Clinical Pipeline: The company maintains a robust pipeline with numerous drug candidates in various stages of development across multiple therapeutic areas, including neurology, cardiometabolic, and rare diseases, reducing reliance on any single asset.

Established Strategic Collaborations: Ionis has a strong history of forming successful, long-term partnerships with major pharmaceutical companies, which provides significant non-dilutive funding, de-risks development, and offers broad commercialization reach.